Esketamine is a refined, more targeted version of ketamine that specifically activates receptors associated with antidepressant effects while minimizing unwanted dissociative or anesthetic side effects. It is the active ingredient in Spravato, an FDA-approved medication for treatment-resistant depression and depression with suicidal thoughts.